Imlifidase

Name: Imlifidase in Kidney transplantation in highly sensitized patients: Humanistic burden and health-related quality of life
Published: 2026-09-14T15:39:06-04:00

Kidney transplantation in highly sensitized patients

Manufacturer: Hansa Biopharma
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of Kidney transplantation in highly sensitized patients

Humanistic burden and health-related quality of life

2 evidence topics · 2 sources

Humanistic burden

“Kidney failure will change your day-to-day activities” (opens the source at this quote in a new tab)

Irish economic model: utility-data limitation

“Another limitation is that utility data specific to highly sensitised ESRD patients were not available.” (opens the source at this quote in a new tab)